The biggest-selling pharma companies of 2023
Propelled by Covid Pfizer surges ahead, but more interest could fall on a cohort of companies driven by newcomer drugs lower down the list.
Biotech’s key upcoming clinical results
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
Big pharma’s new year catalysts
In the opening months of 2023 Novo Nordisk needs to defend its position, while Daiichi and Astrazeneca await ADC data.
Evaluate Vantage 2023 Preview: free to download now
After a tough time for many in biopharma, what does 2023 hold for the sector? Find out in our preview of the year ahead.
The problem with Her2-low testing
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
Few safe havens surface in another down quarter for biopharma
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
Kinnate is the latest Raf player to trip up
The company’s attempt to segment Braf-mutant cancers further isn’t going smoothly.
The gloom deepens for biopharma stocks
With most glimmers of hope extinguished in the third quarter, 2022 is shaping up to be an annus horribilis for sector share prices.
